增强型体外反搏在心血管疾病中的研究进展

doi:10.3969/j.issn.1004-583X.2026.01.013

摘要/Abstract

摘要：

增强型体外反搏(enhanced external counterpulsation,EECP)是一种无创体外循环辅助技术,通过序贯加压臀部及下肢,在舒张期同步提高主动脉根部压力,进而增加冠状动脉灌注与心输出量,改善重要脏器血流供应。本文系统梳理该技术在心血管疾病治疗中的循证证据与作用机制最新进展。临床层面,多项随机对照试验一致证实,EECP可显著缓解难治性心绞痛、提升运动耐量及纽约心功能分级,并改善患者生活质量;机制层面,EECP通过增强血流剪切应力、修复血管内皮功能、促进血管新生与冠状动脉侧支形成、抑制系统性炎症及氧化应激、动员CD34⁺/CD133⁺祖细胞等多重路径发挥心血管保护效应。本综述旨在为EECP的深入机制研究及在心血管领域的规范化推广提供理论依据与未来方向。

中图分类号:

R654.1

牛云霞, 何金丽, 于妍, 杨宝平, 李栋. 增强型体外反搏在心血管疾病中的研究进展[J]. 临床荟萃, 2026, 41(1): 73-77.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.01.013

https://www.lchc.cn/CN/Y2026/V41/I1/73

参考文献 36

[1]	刘明波, 何新叶, 杨晓红, 等. 中国心血管健康与疾病报告2023》概要(心血管疾病流行及介入诊疗状况)[J]. 中国介入心脏病学杂志, 2024, 32(10):541-550.doi: 10.3969/j.issn.1004-8812.2024.10.001.
[2]	Zhou ZF, Wang DJ, Li XM, et al. Effects of enhanced external counterpulsation on exercise capacity and quality of life in patients with chronic heart failure: A meta-analysis[J]. Medicine (Baltimore). 2021, 100(27):e26536. doi: 10.1097/MD.0000000000026536.
[3]	黄雯婷, 张茹欣, 王京, 等. 体外反搏对高血压患者的影响[J]. 中华高血压杂志(中英文), 2025, 33(4):385-388. doi:10.16439/j.issn.1673-7245.2025.04.013.
[4]	Qin X, Deng Y, Wu D, et al. Does enhanced external counterpulsation (EECP) significantly affect myocardial perfusion?: A systematic review & meta-analysis[J]. PLoS One, 2016, 11(4):e0151822. doi: 10.1371/journal.pone.0151822.
[5]	Lishuta AS, Slepova OA, Nikolaeva NA, et al. Cardiovascular effects of long-term treatment with enhanced external counterpulsation in patients with ischemic heart failure: Randomized, placebo-controlled, open-label clinical trial[J]. J Cardiovasc Dev Dis, 2025, 12(9):352.doi: 10.3390/jcdd12090352.
[6]	Lin S, Xiao-Ming W, Gui-Fu W. Expert consensus on the clinical application of enhanced external counterpulsation in elderly people (2019),[J]. Aging Med (Milton), 2020, 3(1):16-24. doi: 10.1002/agm2.12097.
[7]	Xu L, Cui M, Zhao W. The effect of EECP on ischemic heart failure: A systematic review[J]. Curr Cardiol Rep, 2023, 25(10):1291-1298. doi: 10.1007/s11886-023-01943-1.
[8]	Sahebjami F, Madani FR, Komasi S, et al. Refractory angina frequencies during 7 weeks treatment by enhanced external counterpulsation in coronary artery disease patients with and without diabetes[J]. Ann Card Anaesth, 2019, 22(3):278-282. doi: 10.4103/aca.ACA_86_18.
[9]	Zhang Y, Yin X, Ren L. A randomized controlled study of enhanced external counterpulsation with cardiac rehabilitation in patients with nonobstructive coronary artery disease and coronary microvascular dysfunction[J]. Int Heart J, 2024, 65(3):380-385. doi: 10.1536/ihj.23-454.
[10]	Ashokprabhu ND, Fox J, Henry TD, et al. Enhanced external counterpulsation for the treatment of angina with nonobstructive coronary artery disease[J]. Am J Cardiol, 2024, 211:89-93. doi: 10.1016/j.amjcard.2023.10.061.
[11]	Liang J, Shi J, Wei W, et al. External Counterpulsation attenuates hypertensive vascular injury through enhancing the function of endothelial progenitor cells[J]. Front Physiol, 2021, 11:590585. doi: 10.3389/fphys.2020.590585.
[12]	张丹丹, 王少华, 马娟, 等. 增强型体外反搏对老年高血压患者血压的即刻作用和持续影响[J]. 中华老年医学杂志, 2021, 40(12):1512-1515. doi: 10.3760/cma.j.issn.0254-9026.2021.12.008.
[13]	Picard F, Panagiotidou P, Wolf-Pütz A, et al. Individual shear rate therapy (ISRT)-further development of external counterpulsation for decreasing blood pressure in patients with symptomatic coronary artery disease (CAD)[J]. Hypertens Res, 2020, 43(3):186-196. doi: 10.1038/s41440-019-0380-x.
[14]	Duan Y, Tang HX. Efficacy of enhanced extracorporeal counterpulsation combined with atorvastatin in the treatment of cognitive impairment after stroke[J]. World J Psychiatry, 2023, 13(12):1027-1036. doi: 10.5498/wjp.v13.i12.1027.
[15]	Li B, Wang W, Mao B, et al. Hemodynamic effects of enhanced external counterpulsation on cerebral arteries: A multiscale study[J]. Biomed Eng Online, 2019, 18(1):91. doi: 10.1186/s12938-019-0710-x.
[16]	Huang J, Liang M, Jiang D, et al. Enhanced Parkinson's gait, reduced fall risk, and improved cognitive function through multimodal rehabilitation combined with rivastigmine treatment[J]. Am J Transl Res, 2024, 16(6):2379-2388. doi: 10.62347/PAXI7650.
[17]	Yang W, Lu L, Cheng J, He X. Research focus and theme evolution on enhanced external counterpulsation: A bibliometric analysis[J]. Heliyon, 2024, 11(1):e41258. doi: 10.1016/j.heliyon.2024.e41258.doi:10.1016/j.heliyon.2024.e41258.
[18]	李淑妍, 陶新宇, 曲晨. 血管壁面剪切应力对动脉粥样硬化和动脉瘤的影响[J]. 中国动脉硬化杂志, 2024, 32(5):451-455.doi:10.20039/j.cnki.1007-3949.2024.05.012.
[19]	Zhou M, Yu Y, Chen R. Wall shear stress and its role in atherosclerosis[J]. Front Cardiovasc Med, 2023, 10:1083547. doi: 10.3389/fcvm.2023.1083547.
[20]	Gurovich AN, Braith RW. Enhanced external counterpulsation creates acute blood flow patterns responsible for improved flow-mediated dilation in humans[J]. Hypertens Res, 2013, 36(4):297-305. doi: 10.1038/hr.2012.169. Epub 2012 Oct 18.
[21]	Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial dysfunction, inflammation and coronary artery disease: Potential biomarkers and promising therapeutical approaches[J]. Int J Mol Sci, 2021, 22(8):3850. doi: 10.3390/ijms22083850.
[22]	Braith RW, Conti CR, Nichols WW, et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: A randomized sham-controlled study[J]. Circulation, 2010, 122(16):1612-20.doi: 10.1161/CIRCULATIONAHA.109.923482. Epub 2010 Oct 4.
[23]	Yin Q, Jiang H, Zhang Z, et al. Influence of enhanced external counterpulsation on endothelial function: A meta-analysis of randomized controlled trials[J]. Scand Cardiovasc J, 2023, 57(1):2273223. doi: 10.1080/14017431.2023.2273223.
[24]	刘全未, 赵增光, 霍雨佳, 等. 增强型体外反搏对冠状动脉慢血流患者脉搏波传导速度及内皮功能的影响[J]. 心肺血管病杂志, 2019, 38(7):721-724.
[25]	Buschmann EE, Brix M, Li L, et al. Adaptation of external counterpulsation based on individual shear rate therapy improves endothelial function and claudication distance in peripheral artery disease[J]. Vasa, 2016, 45(4):317-24. doi: 10.1024/0301-1526/a000544.
[26]	Caceres J, Atal P, Arora R, et al. Enhanced external counterpulsation: A unique treatment for the “No-Option” refractory angina patient[J]. J Clin Pharm Ther, 2021, 46(2):295-303. doi: 10.1111/jcpt.13330. Epub 2021 Jan 7.
[27]	钱孝贤, 陈燕铭, 吴伟康, 等. 体外反搏对心肌缺血犬SOD和MDA的影响[J]. 中山大学学报(医学科学版), 2006, ( S2):9-11. doi:10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2006.0284.
[28]	Shaker SR, Al-Amran F, Fatima G, et al. Trimetazidine improves the outcome of EECP therapy in patients with refractory angina pectoris[J]. Med Arch, 2020, 74(3):199-204. doi: 10.5455/medarh.2020.74.199-204.
[29]	Sardina PD, Martin JS, Dzieza WK, et al. Enhanced external counterpulsation (EECP) decreases advanced glycation end products and proinflammatory cytokines in patients with non-insulin-dependent type II diabetes mellitus for up to 6 months following treatment[J]. Acta Diabetol, 2016, 53(5):753-60. doi: 10.1007/s00592-016-0869-6.
[30]	Luo JY, Wu GF, Xiong Y, et al. Enhanced external counterpulsation promotes growth cytokines-mediated myocardial angiogenesis in a porcine model of hypercholesterolemia[J]. Chin Med J (Engl), 2009, 122(10):1188-1194.
[31]	Zhang Y, Yin X, Ren L. A randomized controlled study of enhanced external counterpulsation with cardiac rehabilitation in patients with nonobstructive coronary artery disease and coronary microvascular dysfunction[J]. Int Heart J, 2024, 65(3):380-385. doi: 10.1536/ihj.23-454.
[32]	Malhotra R, Bakken K, D'Elia E, et al. Cardiopulmonary exercise testing in heart failure[J]. JACC Heart Fail, 2016, 4(8):607-616. doi: 10.1016/j.jchf.2016.03.022.
[33]	Prasad M, Corban MT, Henry TD, et al. Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease[J]. Cardiovasc Res, 2020, 116(8):1424-1433. doi: 10.1093/cvr/cvaa027.
[34]	Raza A, Steinberg K, Tartaglia J, et al. Enhanced external counterpulsation therapy: Past, present, and future[J]. Cardiol Rev, 2017, 25(2):59-67. doi: 10.1097/CRD.0000000000000122.
[35]	Tartaglia JT, Eisenberg CA, DeMarco JC, et al. Mobilization of endogenous CD34+/CD133+ endothelial progenitor cells by enhanced external counter pulsation for treatment of refractory angina[J]. Int J Mol Sci, 2024, 25(18):10030. doi: 10.3390/ijms251810030.
[36]	Velagapudi P, Turagam M, Kolte D, et al. Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials[J]. Cardiovasc Revasc Med, 2019, 20(3):215-219. doi: 10.1016/j.carrev.2018.05.018.

增强型体外反搏在心血管疾病中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	温贵显, 赵士霞, 张飞飞, 徐兴晨, 刘惠良. 抑郁与中老年CKM 0-3期患者新发CVD的关系:1项追踪7年的回顾性队列研究[J]. 临床荟萃, 2026, 41(1): 18-23.
[2]	李颖, 丛晓强, 刘佳. 新型降脂药物的研究进展[J]. 临床荟萃, 2025, 40(9): 850-854.
[3]	尤佳伟, 安艳新, 吕佳宁, 高晓红, 胡丽艳, 单婕, 陈琳. 中国45岁及以上人群社交活动与心脏疾病的相关性[J]. 临床荟萃, 2025, 40(8): 689-693.
[4]	曹淑风, 杨昌林. 二十碳五烯酸在心血管疾病中的相关研究及临床应用[J]. 临床荟萃, 2025, 40(6): 564-569.
[5]	刘萍, 于猛, 刘明新, 李文锋. 血常规衍生的新型炎症指标与急性前壁ST段抬高型心肌梗死患者PCI术后院内发生不良心血管事件的相关性[J]. 临床荟萃, 2025, 40(5): 400-407.
[6]	王家琦, 谢悦陶, 刘惠良, 张飞飞, 党懿, 李英肖, 齐晓勇. 经皮冠状动脉介入治疗后化脓性心包炎1例并文献复习[J]. 临床荟萃, 2025, 40(12): 1104-1107.
[7]	陕西省川崎病诊疗中心/陕西省人民医院儿童病院, 国家儿童健康与疾病医学研究中心/重庆医科大学附属儿童医院, 国家儿童医学中心/首都医科大学附属北京儿童医院, 上海交通大学医学院附属儿童医院, 国家儿童区域医疗中心/中国医科大学附属盛京医院, 川崎病诊疗基层指南编写委员会, 世界人工意识协会主动医学委员会. 川崎病全科医师诊疗指南(实践版·2025)[J]. 临床荟萃, 2025, 40(10): 869-873.
[8]	张雪, 王俊祥. 类风湿关节炎共病的研究进展[J]. 临床荟萃, 2025, 40(1): 86-89.
[9]	张中楼, 崔坤, 孟晋启. 运动保护心血管系统的研究进展[J]. 临床荟萃, 2024, 39(9): 855-860.
[10]	李星, 冯华平, 蓝胜峰, 李志勇. 不同超声评估方法在左前降支狭窄中的临床价值[J]. 临床荟萃, 2024, 39(8): 693-699.
[11]	马剑楠, 陶杰, 桑大森, 吴寿岭, 张旗. 尿转铁蛋白与2型糖尿病人群新发心血管疾病的关系[J]. 临床荟萃, 2024, 39(8): 700-705.
[12]	张磊, 李新, 郭振峰. 对比冠状动脉内注射替奈普酶与替罗非班对急性ST段抬高型心肌梗死的有效性及安全性[J]. 临床荟萃, 2024, 39(7): 598-602.
[13]	李亚楠, 张红雨. 急性STEMI患者直接PCI时经球囊尾部于冠状动脉内注射小剂量尿激酶原的疗效[J]. 临床荟萃, 2024, 39(6): 518-523.
[14]	庞樱容, 孙欣. sST2在心血管疾病中作用的研究进展[J]. 临床荟萃, 2024, 39(5): 460-465.
[15]	师丽琪, 雷普文, 钱宝堂. 高强度间歇训练在接受经皮冠状动脉介入治疗冠心病患者心脏康复中的研究进展[J]. 临床荟萃, 2024, 39(5): 466-469.